ClinicalTrials.gg
TerminatedNCT05446129Updated Mar 13, 2025Results posted

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

A Phase 1 interventional study of Ezabenlimab and BI 765063 in Colorectal Cancer, sponsored by Boehringer Ingelheim. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Why this study was terminated
Company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim — 1 open to participants now, 2 under way, none of them phase 3. Colorectal Neoplasms · Boehringer Ingelheim.

Enrollment
13th of 14
2 · median 57
Started
2022
the only one that year
Phase 1
5 of 14
none open now
Registered
10th of 14
by date

Among the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, this one is the 13th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 1, and was the 10th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to people with newly diagnosed colorectal cancer. People who are scheduled for surgery can participate. People either get a medicine called BI 765063 combined with ezabenlimab or combined with pembrolizumab in preparation of the upcoming surgery. The tested medicines in this study are antibodies that may help the immune system fight cancer.

The purpose of this study is to find out how well people with early colorectal cancer can tolerate treatment with these medicines. The study also looks at whether the tumor changes.

Participants are put into 2 groups. One group gets ezabenlimab and BI 765063. The other group gets pembrolizumab and BI 765063. All participants receive the study medicines as 2 subsequent infusions into a vein on a single day.

Participants are in the study for about 4 months. During this time, they visit the study site about 5 times. The doctors check the health of the participants and note any health problems that could have been caused by ezabenlimab, pembrolizumab, or BI 765063. The doctors also check whether these health problems lead to a delay of the planned surgery.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial. Ability to understand and the willingness to sign a written informed consent.
  • Male or female aged = 18 years at the time of informed consent form (ICF) signature.
  • Patients with histological diagnosis of resectable colorectal Cancer (CRC), or radiographic/visual findings highly suggestive, with planned confirmatory .
  • CRC lesions must be at least 1 centimeter (cm) in largest diameter and amenable to endoscopic biopsy.
  • Patient must be willing and able to have endoscopic biopsy (Goal 3-6 core-needle or surgical/endoscopic biopsies, final number to be determined by the physician performing the procedure as safe) of tumor prior to initiation of therapy.
  • (ECOG) performance status 0-1. The exception will be patients with long term disability (such as cerebral palsy) that is unlikely to significantly affect their response to therapy.
  • Patient is determined to be a surgical candidate for resection of their tumor.
  • Adequate organ and marrow function as defined in the protocol.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria

  • Patients who are deemed to be at high risk for colonic obstruction and/or perforation per investigator assessment.
  • Patients eligible for therapy (chemotherapy, radiotherapy, chemoradiotherapy) as standard of care.
  • Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to administration of trial medication.
  • Patients who must or wish to continue the intake of restricted medications (as defined in the protocol) or any drug considered likely to interfere with the safe conduct of the trial.
  • Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the patient an unreliable trial participant).
  • Previous enrolment in this trial.
  • Currently enrolled in another device or drug trial, or less than 30 days since ending another investigational device or drug trial(s) or receiving other investigational treatment(s).
  • Patients who have had chemotherapy or radiotherapy within 6 months prior to entering the study for a different primary tumor, or those that have received locoregional therapy (radiation, chemoembolization, etc.) for the target lesion that will be biopsied and subsequently resected. Previous therapy for a different cancer (a different primary) is acceptable.
  • Prior therapy.
  • Patients with or recurrent disease, for which the intent of surgery would not be curative.
  • Further exclusion criteria apply
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Cohort A: Ezabenlimab + BI 765063

    Drug: Ezabenlimab · Drug: BI 765063

  • Experimental
    Cohort B: Pembrolizumab + BI 765063

    Drug: BI 765063 · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Composite Endpoint: Proportion of Patients With at Least One Occurrence of a Safety or Feasibility Event

    Safety: A safety event was defined as any grade 3 or higher adverse events (AEs; according to National Cancer Institute's Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) related to study treatments at any point within the follow-up period following the administration of study treatments. Feasibility (delay in surgery): A feasibility event or delay in surgery was defined as any treatment related AE leading to delay in surgery, which was scheduled to take place between 2 weeks and up to 6 weeks following the study treatment administration will be considered as a relevant AE for this endpoint.

    Time frame: Up to 91 days after drug administration.

Secondary outcomes

  1. Pathologic Response (PR)

    At least 50% or more tumor regression classified as per Mandard tumor regression grading system, in viable adenocarcinoma cells in the surgical specimen, including lymph nodes. Pathological response includes complete pathology response (CR), near complete pathological response (near CR) and partial pathological response

    Time frame: Up to 91 days after drug administration.

  2. Time From Administration of Trial Treatment to Surgery

    Time from administration of trial treatment to surgery, defined as the time in days that elapses between administration of neoadjuvant trial therapy and surgical resection.

    Time frame: Up to 91 days after drug administration.

  3. Radiographic Response Rate

    Radiographic response on pre-surgical imaging, following receipt of the neoadjuvant therapy, as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). The same imaging procedure(s) (computed tomography, magnetic resonance imaging scan) were used throughout the trial.

    Time frame: Up to 91 days after drug administration.

07

Results

Posted Mar 13, 2025
Limitations and caveats
The trial was terminated early due to the sponsor's decision.

Participant flow

An open-label, single-center, two-arm, parallel-group Phase I trial to assess the safety and feasibility of a single dose of BI 765063 in combination with either ezabenlimab (Cohort A) or pembrolizumab (Cohort B) in participants with early-stage, resectable colorectal cancer in a neoadjuvant setting.

Participant flow — Overall Study
MilestoneCohort A: Ezabenlimab + BI 765063Cohort B: Pembrolizumab + BI 765063
Started11
Completed11
Not completed00

Outcome measures

PrimaryComposite Endpoint: Proportion of Patients With at Least One Occurrence of a Safety or Feasibility Event

Safety: A safety event was defined as any grade 3 or higher adverse events (AEs; according to National Cancer Institute's Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) related to study treatments at any point within the follow-up period following the administration of study treatments. Feasibility (delay in surgery): A feasibility event or delay in surgery was defined as any treatment related AE leading to delay in surgery, which was scheduled to take place between 2 weeks and up to 6 weeks following the study treatment administration will be considered as a relevant AE for this endpoint.

Time frame:
Up to 91 days after drug administration.
Reported as:
Number · Percentage of Participants
Composite Endpoint: Proportion of Patients With at Least One Occurrence of a Safety or Feasibility Event
Percentage of ParticipantsEzabenlimab + BI 765063Pembrolizumab + BI 765063
Composite Endpoint: Proportion of Patients With at Least One Occurrence of a Safety or Feasibility Event00
SecondaryPathologic Response (PR)

At least 50% or more tumor regression classified as per Mandard tumor regression grading system, in viable adenocarcinoma cells in the surgical specimen, including lymph nodes. Pathological response includes complete pathology response (CR), near complete pathological response (near CR) and partial pathological response

Time frame:
Up to 91 days after drug administration.
Reported as:
Number · Percentage of Participants
Pathologic Response (PR)
Percentage of ParticipantsEzabenlimab + BI 765063Pembrolizumab + BI 765063
Complete pathology response (CR)00
Near complete pathological response (near CR)00
Partial pathological response00
No response1 (NA to NA)1 (NA to NA)
SecondaryTime From Administration of Trial Treatment to Surgery

Time from administration of trial treatment to surgery, defined as the time in days that elapses between administration of neoadjuvant trial therapy and surgical resection.

Time frame:
Up to 91 days after drug administration.
Reported as:
Mean · days
Time From Administration of Trial Treatment to Surgery
daysEzabenlimab + BI 765063Pembrolizumab + BI 765063
Time From Administration of Trial Treatment to Surgery19 ± NA19 ± NA
SecondaryRadiographic Response Rate

Radiographic response on pre-surgical imaging, following receipt of the neoadjuvant therapy, as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). The same imaging procedure(s) (computed tomography, magnetic resonance imaging scan) were used throughout the trial.

Time frame:
Up to 91 days after drug administration.
Reported as:
Number · Percentage of participants
Radiographic Response Rate
Percentage of participantsEzabenlimab + BI 765063Pembrolizumab + BI 765063
Complete Response (CR)00
Partial Response (PR)00
Progressive Disease (PD)00
Stable Disease (SD)100 (NA to NA)100 (NA to NA)

Adverse events

Collected over Up to 91 days after drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezabenlimab + BI 7650630/1 (0%)0/1 (0%)1/1 (100%)
Pembrolizumab + BI 7650630/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventEzabenlimab + BI 765063Pembrolizumab + BI 765063
AnaemiaBlood and lymphatic system disorders1/10/1
DiarrhoeaGastrointestinal disorders1/10/1
Influenza like illnessGeneral disorders0/11/1
PainGeneral disorders1/10/1
White blood cell count decreasedInvestigations1/10/1
Decreased appetiteMetabolism and nutrition disorders0/11/1
HyperglycaemiaMetabolism and nutrition disorders1/11/1
HypoalbuminaemiaMetabolism and nutrition disorders1/10/1
HypocalcaemiaMetabolism and nutrition disorders1/10/1
HyponatraemiaMetabolism and nutrition disorders1/10/1

Baseline characteristics

As only two participants were enrolled in the study, analysis sets were not defined.

Age, Customized
Age, Customized(Participants)Cohort A: Ezabenlimab + BI 765063Cohort B: Pembrolizumab + BI 765063Total
>= 18 years112
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Ezabenlimab + BI 765063Cohort B: Pembrolizumab + BI 765063Total
Female112
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: Ezabenlimab + BI 765063Cohort B: Pembrolizumab + BI 765063Total
Hispanic or Latino000
Not Hispanic or Latino112
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: Ezabenlimab + BI 765063Cohort B: Pembrolizumab + BI 765063Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https:// www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Aug 2023, 10 months.

Results were first posted in Mar 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Jul 6, 2022
StartActual
Sep 27, 2022
Primary completionActual
Aug 11, 2023
CompletionActual
Nov 8, 2023
Results first posted
Mar 13, 2025
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05446129
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Sep 27, 2022
Primary completion
Aug 11, 2023
Completion
Nov 8, 2023
Results posted
Mar 13, 2025
Last update
Mar 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezabenlimab · Anti-SIRPa Monoclonal Antibody BI 765063

Start the discussion